US 12,264,183 B2
Bacteriocins for control of Salmonella enterica
Simone Hahn, Merseburg (DE); Tobias Schneider, Halle (DE); Anett Stephan, Halle (DE); Steve Schulz, Halle (DE); Anatoli Giritch, Halle (DE); Yuri Gleba, Berlin (DE); and Heike Prochaska, Halle (DE)
Assigned to Nomad Bioscience GmbH, Munich (DE)
Filed by Nomad Bioscience GmbH, Munich (DE)
Filed on Sep. 21, 2021, as Appl. No. 17/480,283.
Application 17/480,283 is a division of application No. 16/577,484, filed on Sep. 20, 2019, granted, now 11,161,886.
Application 16/577,484 is a continuation in part of application No. PCT/EP2018/055479, filed on Mar. 6, 2018.
Claims priority of application No. 17162784 (EP), filed on Mar. 24, 2017.
Prior Publication US 2022/0073575 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/46 (2006.01); A23K 20/147 (2016.01)
CPC C07K 14/461 (2013.01) [A23K 20/147 (2016.05)] 5 Claims
 
1. A composition comprising a protein comprising or consisting of any one of the following amino acid sequences:
(A-x) SEQ ID NO: 28; or
(B-x) an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 28; or
(C-x) an amino acid sequence having at least 80% sequence similarity to the amino acid sequence of SEQ ID NO: 28; or
(D-x) an amino acid sequence having from 1 to 40 amino acid substitutions, additions, insertions or deletions to the amino acid sequence of SEQ ID NO: 28; or
(E-x) an amino acid sequence comprising or consisting of at least 215 contiguous amino acid residues of SEQ ID NO: 28; and
wherein the composition further comprises a protein according to item (A-iii), (B-iii), (C-iii), (D-iii) or (E-iii), and/or according to item (A-vii), (B-vii), (C-vii), (D-vii) or (E-vii), and/or according to item (A-viii), (B-viii), (C-viii), (D-viii) or (E-viii), and/or according to item (A-ix), (B-ix), (C-ix), (D-ix) or (E-ix), or any combination thereof:
(A-iii) SEQ ID NO: 3,
(A-vii) SEQ ID NO: 25,
(A-viii) SEQ ID NO: 26, or
(A-ix) SEQ ID NO: 27;
or
(B-iii) an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 3,
(B-vii) an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 25,
(B-viii) an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 26, or
(B-ix) an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 27;
or
(C-iii) an amino acid sequence having at least 85% sequence similarity to the amino acid sequence of SEQ ID NO: 3,
(C-vii) an amino acid sequence having at least 80% sequence similarity to the amino acid sequence of SEQ ID NO: 25,
(C-viii) an amino acid sequence having at least 80% sequence similarity to the amino acid sequence of SEQ ID NO: 26, or
(C-ix) an amino acid sequence having at least 80% sequence similarity to the amino acid sequence of SEQ ID NO: 27;
or
(D-iii) an amino acid sequence having from 1 to 40 amino acid substitutions, additions, insertions or deletions to the amino acid sequence of SEQ ID NO: 3,
(D-vii) an amino acid sequence having from 1 to 40 amino acid substitutions, additions, insertions or deletions to the amino acid sequence of SEQ ID NO: 25,
(D-viii) an amino acid sequence having from 1 to 40 amino acid substitutions, additions, insertions or deletions to the amino acid sequence of SEQ ID NO: 26,
(D-ix) an amino acid sequence having from 1 to 40 amino acid substitutions, or additions, insertions or deletions to the amino acid sequence of SEQ ID NO: 27;
or
(E-iii) an amino acid sequence comprising or consisting of at least 470 contiguous amino acid residues of SEQ ID NO: 3,
(E-vii) an amino acid sequence comprising or consisting of at least 425 contiguous amino acid residues of SEQ ID NO: 25,
(E-viii) an amino acid sequence comprising or consisting of at least 425 contiguous amino acid residues of SEQ ID NO: 26,
(E-ix) an amino acid sequence comprising or consisting of at least 425 contiguous amino acid residues of SEQ ID NO: 27.